RxDoctor Payments DataLook up a doctor →

Stanislav Weiner, MD

Clinical Cardiac Electrophysiology · Longview, TXNPI 1003801705

Payments from drug & device makers

$2,444,651in general payments, 2019–2025

Across 1,118 payments — averaging $2186.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1.9M
  • Recor Medical Inc$207K
  • Medical Device Business Services, Inc.$108K
  • Impulse Dynamics (USA) Inc.$105K
  • Medtronic$69K
  • Atricure, Inc.$21K
  • plus $17K from 19 others

What the payments were for

  • Consulting fees$48,33819%
  • Speaking & faculty fees$165,78866%
  • Travel & lodging$20,9828%
  • Food & beverage$14,2416%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,444,651 in reported general payments places this provider in the 95th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$593,002
Medicare patients
1,863
Services billed
8,014

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban439$316,985
XareltoRivaroxaban105$91,230
MultaqDronedarone Hcl70$65,037
CorlanorIvabradine Hcl15$8,343
Metoprolol Succinate319$4,639
Dofetilide17$3,392
Ivabradine Hcl11$3,285
Amiodarone Hcl151$2,800
SotalolSotalol Hcl138$1,885
Flecainide Acetate64$1,730
Mexiletine Hcl13$1,138
Metoprolol Tartrate162$998
Digoxin34$814
Carvedilol96$794
Diltiazem 24hr Er (Cd)Diltiazem Hcl20$450

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$165$316,985439 claims
Johnson & JohnsonXarelto$34$91,230105 claims
Sanofi-aventis U.S. LLCMultaq$191$65,03770 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Longview

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →